Genomic Health Announces New Results From Prostate Cancer Study

Genomic Health Announces New Results From Prostate Cancer Study

prostate cancerGenomic Health, Inc. has announced that results from nine studies of Oncotype DX® in prostate, breast, and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid.

This will be the first presentation of very promising results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville, Md.

Patients with newly diagnosed low-risk prostate cancer and their urologists need to know the aggressiveness of their tumor.

Oncotype DX Prostate Cancer Assay is a genomic test performed on a patient’s needle biopsy and provides essential information regarding the biology of a patient’s prostate cancer.

The result is reported as the Genomic Prostate Score or GPS, and provides a more precise, accurate, and individualized risk assessment, all crucial information necessary to help the patient and his physician to decide between active surveillance and immediate treatment.

The GPS works in combination with standard guidelines for determining prostate cancer risk, from very low to intermediate. Within each of these risk groups, the lower the GPS, the more favorable tumor biology, and the less likely it is for a patient to begin immediate treatment with surgery or radiation.

Dr. Jennifer Cullen, Center for Prostate Disease Research, Department of Defense, Rockville, will be presenting prostate cancer results from a study titled “A prospectively-designed study to determine the association of a 17-gene genomic prostate score with recurrence following surgery for localized prostate cancer (PCa)”, suggesting that Oncotype DX can predict a rise in prostate-specific antigen (PSA) following surgery, confirming this test as a predictor of adverse pathology from the biopsy.

Altogether, the data to be presented highlight further clinical validation of the Oncotype DX prostate cancer test, demonstrating its ability to predict both actionable and long term clinical endpoints related to disease aggressiveness. It also demonstrates the consistent importance of assessing multiple, disease relevant, biological pathways to predict tumor behavior.

Leave a Comment

Your email address will not be published. Required fields are marked *